Allurion Tech's FDA Milestone & Debt-Free Plan
Update: 2025-11-11
Description
Allurion Technologies stock surged by nearly 11% in premarket trading following major FDA approval milestones and a plan to become debt-free. The companys Allurion Smart Capsule, seeking FDA Pre-Market Approval, passed crucial inspections and a Day-One-Hundred Meeting with the FDA. Allurion also announced a debt swap for shares of Series B Convertible Preferred Stock and secured $5 million in private placement financing, positioning itself for a potential US launch of its weight loss technology.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
